Analysts See $0.19 EPS for Exelixis, Inc. (EXEL)

October 11, 2018 - By Ash

Exelixis, Inc. (NASDAQ:EXEL) LogoInvestors sentiment increased to 1.28 in Q2 2018. Its up 0.12, from 1.16 in 2018Q1. It is positive, as 41 investors sold Exelixis, Inc. shares while 68 reduced holdings. 55 funds opened positions while 85 raised stakes. 234.21 million shares or 3.66% more from 225.93 million shares in 2018Q1 were reported.
Avalon Advisors Ltd Liability Company has 0.06% invested in Exelixis, Inc. (NASDAQ:EXEL) for 99,633 shares. Susquehanna Int Llp owns 0% invested in Exelixis, Inc. (NASDAQ:EXEL) for 276,898 shares. Sigma Planning Corp stated it has 16,197 shares. Ing Groep Nv holds 0.02% in Exelixis, Inc. (NASDAQ:EXEL) or 43,198 shares. Voya Limited Liability Corporation owns 3.74 million shares for 0.17% of their portfolio. Washington Trust Com reported 2,800 shares stake. Legal And General Grp Public Limited Company, United Kingdom-based fund reported 309,695 shares. Allen Inv Mgmt Ltd Liability Corporation accumulated 0.01% or 13,079 shares. D E Shaw & Incorporated holds 1.71M shares. Profund Advisors Ltd Liability Corporation invested in 0.11% or 123,474 shares. Barclays Public Ltd has invested 0% in Exelixis, Inc. (NASDAQ:EXEL). C Wide Gru Hldgs A S invested in 0% or 11,818 shares. Prudential Inc stated it has 0.01% of its portfolio in Exelixis, Inc. (NASDAQ:EXEL). Cubist Systematic Strategies Limited Liability Company accumulated 17,757 shares or 0.02% of the stock. Natixis, a France-based fund reported 418,054 shares.

Since April 11, 2018, it had 0 insider buys, and 20 selling transactions for $15.59 million activity. FELDBAUM CARL B sold $705,797 worth of stock or 34,262 shares. $1.85M worth of Exelixis, Inc. (NASDAQ:EXEL) was sold by MORRISSEY MICHAEL. Hessekiel Jeffrey sold $447,200 worth of Exelixis, Inc. (NASDAQ:EXEL) on Friday, May 4. Shares for $1.07 million were sold by WILLSEY LANCE. 15,000 Exelixis, Inc. (NASDAQ:EXEL) shares with value of $321,300 were sold by COHEN CHARLES. Another trade for 15,000 shares valued at $285,450 was made by MARCHESI VINCENT T on Friday, May 11.

Analysts expect Exelixis, Inc. (NASDAQ:EXEL) to report $0.19 EPS on November, 7.They anticipate $0.07 EPS change or 26.92 % from last quarter’s $0.26 EPS. EXEL’s profit would be $56.62M giving it 21.17 P/E if the $0.19 EPS is correct. After having $0.28 EPS previously, Exelixis, Inc.’s analysts see -32.14 % EPS growth. The stock decreased 0.80% or $0.13 during the last trading session, reaching $16.09. About 502,734 shares traded. Exelixis, Inc. (NASDAQ:EXEL) has declined 38.03% since October 11, 2017 and is downtrending. It has underperformed by 53.65% the S&P500.

Exelixis, Inc. (NASDAQ:EXEL) Ratings Coverage

Among 3 analysts covering Exelixis (NASDAQ:EXEL), 0 have Buy rating, 1 Sell and 2 Hold. Therefore 0 are positive. Exelixis had 4 analyst reports since May 3, 2018 according to SRatingsIntel. The rating was maintained by Stifel Nicolaus with “Hold” on Thursday, May 3. The firm has “Hold” rating by Stifel Nicolaus given on Wednesday, August 1.

Exelixis, Inc., a biopharmaceutical company, engages in the discovery, development, and commercialization of new medicines with the potential to enhance care and outcomes for people with cancer. The company has market cap of $4.80 billion. The company's products include CABOMETYX for the treatment of patients with advanced renal cell carcinoma, who have received prior anti-angiogenic therapy; and COMETRIQ for the treatment of patients with progressive, metastatic medullary thyroid carcinoma. It has a 15.61 P/E ratio. The Company’s CABOMETYX and COMETRIQ are derived from cabozantinib, an inhibitor of multiple tyrosine kinases, including MET, AXL, and VEGF receptors, which has shown clinical anti-tumor activity in approximately 20 forms of cancer and is the subject of a broad clinical development program.

Another recent and important Exelixis, Inc. (NASDAQ:EXEL) news was published by which published an article titled: “Exelixis: An Updated View” on September 14, 2018.

Exelixis, Inc. (NASDAQ:EXEL) Institutional Positions Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.


Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our FREE daily email newsletter:

Recent Market News